Literature DB >> 31183192

Fibroblast growth factor 7 signalling is disrupted in colorectal cancer and is a potential marker of field cancerisation.

Abhilasha Patel1,2, Gyanendra Tripathi2, Philip McTernan2, Kishore Gopalakrishnan3, Omar Ali2, Emma Spector2, Nigel Williams1, Ramesh P Arasaradnam2,4,5,6.   

Abstract

BACKGROUND: Field cancerisation proposes that there are pre-malignant genetic mutations in the macroscopically normal mucosal tissue around colorectal cancer. This study aims to evaluate fibroblast growth factor 7 (FGF7) tissue expression in the mucosal field around colorectal cancer.
METHODS: Gene and protein expression of FGF7, its receptor, FGFR2 and its downstream targets; FRS2α, Erk 1/2 and Akt was measured from mucosal samples in 34 control subjects and 17 cancer patients. Serial samples from tumour, adjacent to tumour and at the resection margin were utilised.
RESULTS: FGF7 gene expression was significantly higher in tumour (2.3-fold), adjacent mucosa (3.2-fold) and resection margin (2.8-fold) of cancer patients compared with control subjects (P<0.01 respectively). However, FGFR2 was down regulated (3.5-fold) in the tumour tissue (P<0.001). Protein expression of FRS2α and Akt was significantly lower in tumour tissue compared with the resection margin in cancer patients (P<0.05 respectively). No differences in protein expression of Erk 1/2 were detected.
CONCLUSIONS: FGF7 was elevated in the mucosal field of cancer patients supporting its potential as a biomarker of field cancerisation. Changes in FRS2α, Akt and Erk 1/2 expression in the tumour tissue indicate that with malignant transformation, FGF7 loses its ability to regulate cellular differentiation.

Entities:  

Keywords:  Fibroblast growth factor; colorectal cancer; field cancerisation

Year:  2019        PMID: 31183192      PMCID: PMC6534718          DOI: 10.21037/jgo.2019.02.11

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  21 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Cellular signaling by fibroblast growth factor receptors.

Authors:  V P Eswarakumar; I Lax; J Schlessinger
Journal:  Cytokine Growth Factor Rev       Date:  2005-02-01       Impact factor: 7.638

3.  Overexpression of keratinocyte growth factor in cancer cells and enterochromaffin cells in human colorectal cancer.

Authors:  M Watanabe; T Ishiwata; K Nishigai; Y Moriyama; G Asano
Journal:  Pathol Int       Date:  2000-05       Impact factor: 2.534

4.  Expression of keratinocyte growth factor and its receptor in colorectal cancer.

Authors:  J M Otte; F Schmitz; T Banasiewicz; M Drews; U R Fölsch; K H Herzig
Journal:  Eur J Clin Invest       Date:  2000-03       Impact factor: 4.686

5.  Keratinocyte growth factor receptor expression in normal colorectal epithelial cells and differentiated type of colorectal cancer.

Authors:  Masanori Yoshino; Toshiyuki Ishiwata; Masanori Watanabe; Osamu Komine; Tetsuo Shibuya; Akira Tokunaga; Zenya Naito
Journal:  Oncol Rep       Date:  2005-02       Impact factor: 3.906

6.  Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.

Authors:  Thomas Amann; Frauke Bataille; Thilo Spruss; Katja Dettmer; Peter Wild; Christian Liedtke; Marcus Mühlbauer; Paul Kiefer; Peter J Oefner; Christian Trautwein; Anja-Katrin Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

Review 7.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

8.  Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate.

Authors:  Benyoussef Naimi; Alain Latil; Georges Fournier; Philippe Mangin; Olivier Cussenot; Philippe Berthon
Journal:  Prostate       Date:  2002-08-01       Impact factor: 4.104

9.  Mechanisms of KGF mediated signaling in pancreatic duct cell proliferation and differentiation.

Authors:  Benjamin Uzan; Florence Figeac; Bernard Portha; Jamileh Movassat
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

10.  Clinical implications and utility of field cancerization.

Authors:  Gabriel D Dakubo; John P Jakupciak; Mark A Birch-Machin; Ryan L Parr
Journal:  Cancer Cell Int       Date:  2007-03-15       Impact factor: 5.722

View more
  3 in total

1.  Genotyping Helicobacter pylori and fgf7 gene expression in gastric cancer.

Authors:  Manouchehr Ahmadi Hedayati; Delniya Khani; Hamed Bashiri
Journal:  Mol Biol Rep       Date:  2022-07-07       Impact factor: 2.742

2.  Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer.

Authors:  Aida Ferreiro-Iglesias; James D McKay; Nicole Brenner; Shama Virani; Corina Lesseur; Valerie Gaborieau; Andy R Ness; Rayjean J Hung; Geoffrey Liu; Brenda Diergaarde; Andrew F Olshan; Neil Hayes; Mark C Weissler; Lea Schroeder; Noemi Bender; Michael Pawlita; Steve Thomas; Miranda Pring; Tom Dudding; Beatriz Kanterewicz; Robert Ferris; Sera Thomas; Yonathan Brhane; Virginia Díez-Obrero; Maja Milojevic; Karl Smith-Byrne; Daniela Mariosa; Mattias J Johansson; Rolando Herrero; Stefania Boccia; Gabriella Cadoni; Martin Lacko; Ivana Holcátová; Wolfgang Ahrens; Pagona Lagiou; Areti Lagiou; Jerry Polesel; Lorenzo Simonato; Franco Merletti; Claire M Healy; Bo T Hansen; Mari Nygård; David I Conway; Sylvia Wright; Tatiana V Macfarlane; Max Robinson; Laia Alemany; Antonio Agudo; Ariana Znaor; Christopher I Amos; Tim Waterboer; Paul Brennan
Journal:  Nat Commun       Date:  2021-10-12       Impact factor: 14.919

3.  Construction and Validation of an Autophagy-Related Prognostic Signature and a Nomogram for Bladder Cancer.

Authors:  Xin Yan; Hua-Hui Wu; Zhao Chen; Guo-Wei Du; Xiao-Jie Bai; Kurerban Tuoheti; Tong-Zu Liu
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.